# US 2021/0228571 A1 · Methods and compositions for treating cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0228571 A1
- Document ID: US20210228571A1
- Status: Published application
- Kind: A1
- Application number: 17/219,394
- Filed: 2021-03-31
- Published: 2021-07-29
- Earliest claimed: 2019-07-15
- Assignees: Rovaxa
- Applicants: Rovaxa
- Inventors: Bryan S. Margulies; Nikhil A. Thakur
- Web page: https://patentgrep.com/patent/US20210228571A1

## CPC

- A61K 31/485: Morphinan derivatives, e.g. morphine, codeine
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0024: {Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L)}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 45/00: Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K 47/20: containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61K 47/42: Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein (oligopeptides having up to five amino acids {A61K47/183}; polyamino acids A61K47/34)
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This disclosure relates to methods and compositions for treating cancer by administering opioid growth factor receptor (OGFR) antagonists. In particular, the present disclosure relates to methods of administering OGFR antagonists locally to the site of cancer cells in the patient diagnosed with cancer.

## Claims

### Claim 1

A method of treating a cancer in a subject in need thereof, comprising locally administering an opioid growth factor receptor (OGFR) antagonist to a site in the subject containing cancer cells.

### Claim 2 (depends on 1)

The method of claim 1, wherein the OGFR antagonist comprises naloxone, naltrexone, a functional derivative or analog thereof, or a combination thereof.

### Claim 3 (depends on 1)

The method of claim 1, wherein the cancer comprises soft tissue non-osteogenic sarcomas, bone sarcomas, osteosarcoma, Ewing's sarcoma, chondrosarcoma, benign bone tumors, basal cell carcinoma, melanoma, thyroid adenocarcinomas, glial blastoma, pituitary tumors, oligodendrocytoma, bladder carcinoma, triple negative breast carcinoma, breast carcinoma, neuroblastoma, or astrocytoma.

### Claim 4 (depends on 1)

The method of claim 1, wherein the OGFR antagonist is administered at a local dosage of about 1 mM to about 10 mM.

### Claim 5 (depends on 1)

The method of claim 1, wherein the OGFR antagonist is administered locally by intratumoral injection.

### Claim 6 (depends on 1)

The method of claim 1, wherein the OGFR antagonist is administered with a pharmaceutically acceptable carrier.

### Claim 7 (depends on 6)

The method of claim 6, wherein the pharmaceutically acceptable carrier comprises a collagen based carrier in the form of a collagen sponge, a powdered collagen, or a collagen based gelatin hydrogel.

### Claim 8 (depends on 7)

The method of claim 7, wherein the pharmaceutically acceptable carrier is the collagen sponge.

### Claim 9 (depends on 6)

The method of claim 6, wherein the pharmaceutically acceptable carrier comprises a hydrogel based carrier.

### Claim 10 (depends on 9)

The method of claim 9, wherein the hydrogel based carrier comprises a poly-(lactic acid)/poly-(ethylene glycol)/poly-(lactic acid) hydrogel, a poly-(ethylene glycol)/poly-(lactic acid)/poly-(ethylene glycol) hydrogel, or a combination thereof.

### Claim 11 (depends on 10)

The method of claim 10, wherein the hydrogel based carrier is poly-(ethylene glycol)/poly-(lactic acid)/poly-(ethylene glycol).

### Claim 12 (depends on 1)

The method of claim 1, wherein the OGFR antagonist is administered with a diluent, wherein the diluent enhances the solubility of the OGFR antagonist.

### Claim 13 (depends on 12)

The method of claim 12, wherein the diluent comprises a dimethylsulfoxide (DMSO) based saline solution, or an acidified saline solution.

### Claim 14 (depends on 13)

The method of claim 13, wherein the diluent is the dimethylsulfoxide (DMSO) based saline solution.

### Claim 15 (depends on 14)

The method claim 14, wherein the DMSO based saline solution comprises from about 1% volume/volume (v/v) DMSO to about 80% v/v DMSO.

### Claim 16 (depends on 14)

The method of claim 14, wherein the DMSO based saline solution comprises about 50% v/v DMSO.

### Claim 17 (depends on 13)

The method of claim 13, wherein the acidified saline based solution exhibits a pH from about 4.5 to about 7.4.
